cp wire

CP Wire Articles

AmpliPhi Recieves Positive FDA Feedback for its Bacteriophage Candidate AB-PA01 Development Plans Targeting Pseudomonas Aeruginosa Infections
  • Company received positive written response from FDA regarding development plans
  • Resistant P. aeruginosa is designated as ‘Priority 1: Critical’ pathogen by the World Health... read more
Tue, 09/18/18 - 09:07 am
Ph II Trials of DPX-Survivac in Combination with Ketruda Yield Positive Results in Patients With Diffuse Large B-cell Lymphoma
  • Two of the first four evaluable participants showed tumor regressions at the first on-treatment CT scan
  • DPX-Survivac has received fast-track status from FDA
  • It also has... read more
Tue, 09/18/18 - 08:45 am
Bacteriophage Company Reports Success With Expanded Access Program For Resistant Infections



AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections... read more

Mon, 09/17/18 - 09:08 am
AI Company Enters Into Evaluation Agreement With Pfizer
  • AtomWise raised $45 million in Series A in March of 2018
  • Partners Include: Merck, Abbvie, and Bayer


Atomwise Inc., a leader in Artificial Intelligence (AI) for drug... read more

Mon, 09/17/18 - 08:55 am
Sun Pharma Announce FDA Approval of Xelpros to Treat Open-angle Glaucoma or Ocular Hypertension
  • Xelpros is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK)
  • BAK is associated with increased incidence of Ocular Surface Disease (OSD)... read more
Fri, 09/14/18 - 09:48 am

Pages